The prospect of Lundbeck and Otsuka’s Rexulti becoming part of a new treatment for post-traumatic stress disorder (PTSD) appears more unlikely after a Friday meeting of experts in the field.
PTSD Treatment Dealt a Setback at FDA
Comment
Show comments
Hide Comments
